ÂÜÀòÂÒÂ×

Duncan Hay is a computational chemistry principal research scientist at Vertex Pharmaceuticals, where they apply their extensive expertise in pharmaceutical and academic settings. Previously, Duncan worked as a medicinal chemist at The Structural Genomics Consortium, where they discovered a chemical probe for the CBP/p300 bromodomain. They held the position of senior scientist at Evotec, leading teams in preclinical drug discovery and contributing to multiple patent applications. Duncan’s foundational experience includes roles at GSK and Pfizer, where they developed synthetic routes for complex targets and introduced advanced technologies in chemistry. Duncan earned a first-class honors degree in Chemistry from the University of Edinburgh and a DPhil in Organic Chemistry from the University of Oxford.